Recreational drug user preferences: Egalet® opioids have low abuse and tampering attractiveness relative to marketed opioids

Clinical Efficacy and Safety of Once-Daily Dosing of a Novel, Prolonged-Release Oral Morphine Tablet Compared With Twice-Daily Dosing of a Standard Controlled-Release Morphine Tablet in Patients With Cancer Pain: A Randomized, Double-Blind, Exploratory Crossover Study

“…As an additional advantage, a recent noninterventional interview study in recreational drug users has confirmed that the physical and chemical properties of ADPREM may give rise to low abuse and tampering attractiveness compared with seven well-known marketed opioids. 21 In conclusion, the results of this exploratory first-in-patients study show that ADPREM dosed once daily provides similar trough plasma levels of morphine and analgesic efficacy as CRM, another commonly used CR morphine product, dosed twice daily in cancer patients with chronic pain. No end-of-dose failure was detected at the end of the 24-hour dosing interval for ADPREM, confirming the intended once-daily dosage regimen for the formulation.…”